Global Blood Therapeutics and Syros Pharmaceuticals partner for sickle cell therapiesMarket Watch • 12/18/19
GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta ThalassemiaGlobeNewsWire • 12/18/19
Global Blood Therapeutics: FDA Approval Of Oxbryta Moves Company Into A Large Market OpportunitySeeking Alpha • 11/26/19
This Biotech Broke Out Bullishly — But Couldn't Hold Onto That GainInvestors Business Daily • 11/26/19
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell DiseaseGlobeNewsWire • 11/25/19
Global Blood Therapeutics: Expectations Swell As Voxelotor Marketization NearsSeeking Alpha • 10/23/19
GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with VoxelotorGlobeNewsWire • 10/21/19